Dados B3 › GEPA4 × CPFE3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | GEPA4 | CPFE3 | year |
|---|---|---|---|
| ROE | 36.5%! | 31.5% | 2023 |
| ROIC | 28.1%! | 18.4% | 2023 |
| ROA | 18.4%! | 7.6% | 2023 |
| Gross margin | 38.6%! | 34.3% | 2023 |
| EBIT margin | 35.5%! | 26.6% | 2023 |
| Net margin | 24.5%! | 13.9% | 2023 |
| Net debt/EBITDA | 0.00x! | 1.63x | 2023 |
| Current ratio | 0.42x | 1.02x | 2022 |
| Revenue growth (1y) | -100.0%! | 7.3% | 2024 |
| Revenue growth (5y CAGR) | 1.1%! | 7.2% | 2023 |
| Piotroski F-Score | 1/9! | 6/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | GEPA4 | CPFE3 | year |
|---|---|---|---|
| P/E | 7.23x | 9.86x | 2023 × 2025 |
| P/B | — | 2.41x | 2023 × 2025 |
| EV/EBITDA | 3.25x | 5.97x | 2023 × 2025 |
| FCF yield | 21.5% | 12.5% | 2023 × 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:55 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it